Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.8 million for Q2 2025.

• In Q2 2025, Other Accumulated Expenses rose 66.42% year-over-year to $1.8 million; the TTM figure through Jun 2025 stood at $1.8 million (up 66.42% YoY), while the FY2024 annual figure was $901000.0, down 72.42% from the prior year.
• Other Accumulated Expenses for Q2 2025 stood at $1.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.3 million in Q4 2023, with the low at $323000.0 in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $906500.0 (2021), against an average of $1.0 million.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses jumped 875.22% in 2023, then plunged 72.42% in 2024.
• Crinetics Pharmaceuticals' Other Accumulated Expenses stood at $323000.0 in 2021, then advanced by 3.72% to $335000.0 in 2022, then surged by 875.22% to $3.3 million in 2023, then slumped by 72.42% to $901000.0 in 2024, then soared by 99.67% to $1.8 million in 2025.
• Business Quant data shows CRNX's Other Accumulated Expenses at $1.8 million in Q2 2025, $1.7 million in Q1 2025, and $901000.0 in Q4 2024.